Skip to content
Catalyst
Search

Papers/PMID:25937055

Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial.

Diabetes & metabolism2015The record

4 findings · 1 compound · 4 endpoints

What it reported

How to read these marks

What moved

4 findings

  • magnesium(2+) — decreases triglycerides

    Evidence strength: very limited.Findingreplicated ×1
    “At the end of follow-up, fasting (86.9 ± 7.9 and 98.3 ± 4.6 mg/dL, respectively; P = 0.004) and post-load glucose (124.7 ± 33.4 and 136.7 ± 23.9 mg/dL, respectively; P = 0.03) levels, HOMA-IR indices (2.85 ± 1.0 and 4.1 ± 2.7, respectively; P = 0.04) and triglycerides (166.4 ± 90.6 and 227.0 ± 89.7, respectively; P = 0.009) were significantly decreased, whereas HDL cholesterol (45.6 ± 10.9 and 46.8 ± 9.2 mg/dL, respectively; P = 0.04) and serum magnesium (1.96 ± 0.27 and 1.60 ± 0.26 mg/dL, respectively; P = 0.005) levels were significantly increased in those taking MgCl2 compared with the controls.”
    Quoted verbatim from Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial..
    Study
    RCT
    Dose
    30 mL of MgCl2 5% solution (382 mg magnesium) once daily for four months
    Population
    Adults aged 30 to 65 years with hypomagnesaemia and newly diagnosed prediabetes; MgCl2 solution versus inert placebo solution

    Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial.2015PMID:2593705510.1016/j.diabet.2015.03.010Permalink

  • magnesium(2+) — decreases HOMA-IR

    Evidence strength: very limited.Findingreplicated ×4
    “At the end of follow-up, fasting (86.9 ± 7.9 and 98.3 ± 4.6 mg/dL, respectively; P = 0.004) and post-load glucose (124.7 ± 33.4 and 136.7 ± 23.9 mg/dL, respectively; P = 0.03) levels, HOMA-IR indices (2.85 ± 1.0 and 4.1 ± 2.7, respectively; P = 0.04) and triglycerides (166.4 ± 90.6 and 227.0 ± 89.7, respectively; P = 0.009) were significantly decreased, whereas HDL cholesterol (45.6 ± 10.9 and 46.8 ± 9.2 mg/dL, respectively; P = 0.04) and serum magnesium (1.96 ± 0.27 and 1.60 ± 0.26 mg/dL, respectively; P = 0.005) levels were significantly increased in those taking MgCl2 compared with the controls.”
    Quoted verbatim from Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial..
    Study
    RCT
    Dose
    30 mL of MgCl2 5% solution (382 mg magnesium) once daily for four months
    Population
    Adults aged 30 to 65 years with hypomagnesaemia and newly diagnosed prediabetes; MgCl2 solution versus inert placebo solution

    Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial.2015PMID:2593705510.1016/j.diabet.2015.03.010Permalink

  • magnesium(2+) — decreases fasting blood glucose

    Evidence strength: very limited.Findingreplicated ×11
    “At the end of follow-up, fasting (86.9 ± 7.9 and 98.3 ± 4.6 mg/dL, respectively; P = 0.004) and post-load glucose (124.7 ± 33.4 and 136.7 ± 23.9 mg/dL, respectively; P = 0.03) levels, HOMA-IR indices (2.85 ± 1.0 and 4.1 ± 2.7, respectively; P = 0.04) and triglycerides (166.4 ± 90.6 and 227.0 ± 89.7, respectively; P = 0.009) were significantly decreased, whereas HDL cholesterol (45.6 ± 10.9 and 46.8 ± 9.2 mg/dL, respectively; P = 0.04) and serum magnesium (1.96 ± 0.27 and 1.60 ± 0.26 mg/dL, respectively; P = 0.005) levels were significantly increased in those taking MgCl2 compared with the controls.”
    Quoted verbatim from Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial..
    Study
    RCT
    Dose
    30 mL of MgCl2 5% solution (382 mg magnesium) once daily for four months
    Population
    Adults aged 30 to 65 years with hypomagnesaemia and newly diagnosed prediabetes; MgCl2 solution versus inert placebo solution

    Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial.2015PMID:2593705510.1016/j.diabet.2015.03.010Permalink

  • magnesium(2+) — increases serum magnesium concentration

    Evidence strength: very limited.Findingreplicated ×12
    “At the end of follow-up, fasting (86.9 ± 7.9 and 98.3 ± 4.6 mg/dL, respectively; P = 0.004) and post-load glucose (124.7 ± 33.4 and 136.7 ± 23.9 mg/dL, respectively; P = 0.03) levels, HOMA-IR indices (2.85 ± 1.0 and 4.1 ± 2.7, respectively; P = 0.04) and triglycerides (166.4 ± 90.6 and 227.0 ± 89.7, respectively; P = 0.009) were significantly decreased, whereas HDL cholesterol (45.6 ± 10.9 and 46.8 ± 9.2 mg/dL, respectively; P = 0.04) and serum magnesium (1.96 ± 0.27 and 1.60 ± 0.26 mg/dL, respectively; P = 0.005) levels were significantly increased in those taking MgCl2 compared with the controls.”
    Quoted verbatim from Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial..
    Study
    RCT
    Dose
    30 mL of MgCl2 5% solution (382 mg magnesium) once daily for four months
    Population
    Adults aged 30 to 65 years with hypomagnesaemia and newly diagnosed prediabetes; MgCl2 solution versus inert placebo solution

    Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial.2015PMID:2593705510.1016/j.diabet.2015.03.010Permalink